Ensights

Have you ever needed to perform a test only to be held up by wait times for a single-use component? Perhaps you just need a small order of tubing or connectors, without everything that comes with a bulk order? We want to help customers get the right quantity of components when they need them. That’s why Entegris is proud to announce a new relationship with Qosina, a leading global supplier of OEM single-use components to the medical and pharmaceutical industries.

The growth of the biomanufacturing industry has created a demand for new and high-performance fluid handling systems and technologies for the management and storage of cell and gene therapy intermediates and gene-based medicines. New modalities come with risks that don’t yet have good solutions.

Powder can be a mess when not delt with properly. Have you ever dropped a bag of flour on the floor after coming home from the store? Cleaning up the mess is terrible (speaking from experience, don’t add water or you just make glue). Now imagine doing that in a manufacturing suite with powdered media. The powder is literally designed to grow cells, so anything you miss is just a new petri dish that can generate contamination. Plus, there’s the added challenge of having to validate that the room is clean after attending to the spill.

Entegris is delighted to announce our new interactive tool intended to help the life sciences industry better understand how we can support the entire drug manufacturing process. Our growing life sciences portfolio can be overwhelming for customers, and this simple tool helps guide them to finding all the ways we can help. The tool was designed to be versatile and can be shared by our team as part of a sales overview, or you can explore it yourself to quickly learn more about the solutions we offer.

Biopharma manufacturing is an essential part of the healthcare industry, producing lifesaving treatments for patients around the world. Traditional manufacturing methods can have a significant environmental impact driven by stainless steel equipment requiring extensive cleaning and sterilization processes that consume substantial amounts of water and energy in addition to cleaning agents.

Entegris is delighted to announce our collaboration with Agilitech, a pioneering partner to the biotech industry. Agilitech provides highly flexible, scalable, and future-proof single-use technologies for every step of the bioprocess. These include chromatography systems, mixers, and custom-tailored bioprocess controllers that scale from the laboratory to commercial production environments. This makes them a natural fit for the unique needs of life sciences customers.

By: Mike Lamach, Reach-In Sales Leader, FARRAR™ | Trane Technologies The explosion of needs for -80°C through -60°C assets over the past decade has been nothing short of remarkable. Clinical research investments keep expanding while commercial-scale needs continue to transform the landscape.

HOF Sonderanlagenbau GmbH has been a leader in freezer technology since 1988 under founders Hans-George Hof and Herrmann Schäfer in Lohra, Germany. Through technical knowledge and entrepreneurship, HOF has grown into a global freezer and service operation, specializing in freeze-drying systems for the pharmaceutical and biotechnology industries, serving 28 countries, with 40 customer sites and more than 100 freeze/thaw units serving the biotech and pharmaceutical market.

Whether you’re new to cold chain or a seasoned freeze/thaw pro, it can be difficult to find value-driven solutions for configuring freeze/thaw (F/T) biologic treatments and therapies. Complex cold chain demands are not one-size-fits-all and your team’s time is precious, which is why we created our Cold Chain Guidance Tool. This innovative tool guides you through common decision-making scenarios, analyzes your inputs, and provides you with an assessment of the biggest drivers to achieve optimal results from your process.

As the chief technologist for the Life Sciences Division at Trane Technologies, Scott Farrar knows a thing or two about ultra-low temperature control for the life sciences industry, perhaps drawing inspiration from his days at Penn State University enjoying peach ice cream. Scott’s biggest inspiration, however, was his entrepreneurial dad who started a solar equipment company, teaching Scott from a young age the importance of sciences, technology, engineering, and mathematics (STEM) education and solving problems. Scott carried those tools with him, and upon completing his formal education, went to work for a pharmaceutical manufacturing company in research and development, specializing in low-temp freezers and incubators as well as heat-momentum and mass-transfer-type processes for the pharmaceutical industry. His exposure to dilemmas and investigative approach is what drove him to create better customer experiences.

Like the human body, cell and gene therapy is complex. Specialized cells can be lost through age, injury or disease, and such loss cannot always be replenished by healthy cells, rendering the patient extremely sick or even fatally ill. In many cases, the patient has minimal time to live, with very few cells for transplantation. Thanks to advances in both cell and gene therapies, patients have options as these interventions continue to advance. Cellular therapy includes immunotherapies, vaccinations, and cancer vaccines. While gene therapy aims to modify or alter the biological properties of living cells for therapeutic use. As these interventions are distinct, their manufacturing processes often intersect, leaving opportunities for therapeutic enablement.